Skip to main content

Table 1 Patient baseline demographics and disease characteristics and background N[t]RTIs

From: Cobicistat-boosted darunavir in HIV-1-infected adults: week 48 results of a Phase IIIb, open-label single-arm trial

  All patients N = 313 Treatment-naïve patients N = 295
Male [n (%)] 279 (89) 266 (90)
Age, years [median (range)] 35 (18–72) 34 (18–72)
Race [n (%)]   
 White 187 (60) 176 (60)
 Black or African Heritage 108 (35) 101 (34)
 Asian 4 (1) 4 (1)
 Other 14 (4) 14 (5)
Log10 VL (HIV-1 RNA copies/ml) [median (range)] 4.8 (2.6–7.0) 4.8 (2.6–7.0)
 VL >100,000 HIV-1 RNA copies/ml [n (%)] 131 (42) 122 (41)
CD4+ cell count (cells/mm3) [median (range)] 361 (5–1473) 370 (6–1473)
 ≤200 cells/mm3 [n (%)] 59 (19) 47 (16)
Asymptomatic HIV infection [n (%)] 251 (80) 241 (82)
Co-infection with HBV [n (%)] 5 (2) 5 (2)
Co-infection with HCV [n (%)] 8 (3) 7 (2)
eGFRCG, ml/min [median (range)] 114 (67–321) 115 (67–321)
Background N[t]RTIs [n (%)]   
 Emtricitabine/tenofovir 301 (96) 291 (99)
 Emtricitabine/tenofovir plus zidovudine 5 (2) 0
 Abacavir plus tenofovir 3 (1) 2 (0.7)
 Emtricitabine/tenofovir plus abacavir 2 (0.6) 1 (0.3)
 Abacavir/lamivudine 1 (0.3) 1 (0.3)
 Didanosine plus emtricitabine 1 (0.3) 0
  1. N number of patients; n number of patients with observations; VL viral load; HBV hepatitis B virus; HCV hepatitis C virus; eGFR CG estimated glomerular filtration rate calculated using the Cockcroft-Gault method; N[t]RTIs nucleoside/tide reverse transcriptase inhibitors.